Clinical Trial Update: The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel plus S-1 as first-line treatment for advanced biliary tract adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Aiping Zhou | Conditions: Biliary Tract Cancer | Phase 2 | Status: COMPLETED